REGN

Regeneron Pharmaceuticals (REGN) is the lead sponsor of 97 active clinical trials listed on ClinicalTrials.gov^[5], including 30 Phase 3^[1], 42 Phase 2^[2], 31 Phase 1^[3], 2 Phase 4^[4].

Trial NCT05394116^[6] evaluates Garetosmab in Fibrodysplasia Ossificans Progressiva with a target enrollment of 63 participants. Trial NCT06230224^[7] evaluates Odronextamab in B-Cell Non-Hodgkin Lymphoma (B-NHL) with a target enrollment of 216 participants. Trial NCT07222761^[8] evaluates Linvoseltamab in Relapsed and/or Refractory Multiple Myeloma (RRMM) with a target enrollment of 915 participants.

REGN has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[9].